Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 6, 2014, Pages 1921-1923

  Danion, F ^a,b,c   Belissa, E ^d   Peytavin, G ^d,e   Thierry, E ^f   Lanternier, F ^a,b,c   Scemla, A ^a,b   Lortholary, O ^a,b,c   Delelis, O ^f   Avettand Fenoel, V ^a,b   Duvivier, C ^a,b,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c IMAGINE INSTITUTE   (France)

^d BICHAT HOSPITAL   (France)

^e INSERM   (France)

^f Ecole Normale Superieure de Cachan   (France)

Author keywords

Dolutegravir resistance; E157Q mutation; HIV treatment; INSTIs; Integrase strand transfer inhibitors

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INTEGRASE; MYCOPHENOLATE MOFETIL; PREDNISONE; RALTEGRAVIR; TACROLIMUS; THYMOCYTE ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS;

CD4+ T LYMPHOCYTE; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FLU LIKE SYNDROME; GENE MUTATION; HEPATITIS C VIRUS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC50; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LETTER; NONHUMAN; THRUSH; TREATMENT RESPONSE; VIRUS LOAD; WEIGHT REDUCTION; WESTERN BLOTTING; ANTIVIRAL RESISTANCE; CASE REPORT; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MALE; MISSENSE MUTATION; VIROLOGY;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HETEROCYCLIC COMPOUNDS, 3-RING; HIV; HIV INFECTIONS; HIV INTEGRASE; HUMANS; MALE; MUTATION, MISSENSE;

EID: 84930514309     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv012     Document Type: Letter

References (9)

1. Jung BH, Rezk NL, Bridges AS et al. Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21: 1095-104.
2. AC11-Resistance-Group-2013. HIV-1 Genotypic Drug Resistance Interpretation's Algorithms From French National Agency for Research on AIDS. http://www.hivfrenchresistance.org.
3. Delelis O, Parissi V, Leh H et al. Efficient and specific internal cleavage of a retroviral palindromic DNA sequence by tetrameric HIV-1 integrase. PLoS One 2007; 2: e608.
4. Castagna A, Maggiolo F, Penco G et al. Dolutegravir in antiretroviralexperienced patients with raltegravir-and/or elvitegravir-resistant HIV-1:24-week results of the phase III VIKING-3 study. J Infect Dis 2014; 210: 354-62.
5. Van Lunzen J, Maggiolo F, Arribas JR et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 12: 111-8.
6. Walmsley SL, Antela A, Clumeck N et al. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 2013; 369: 1807-18.
7. Clotet B, Feinberg J, van Luzen J et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 2014; 383: 2222-31.
8. Cahn P, Pozniak AL, Mingrone H et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV:week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013; 382: 700-8.
9. Malet I, Gimferrer Arriaga L, Artese A et al. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors. J Antimicrob Chemother 2014; 69: 2118-22.